Roche Holding Ltd. (ROG) Given Buy Rating at JPMorgan Chase & Co.
Roche Holding Ltd. (VTX:ROG)‘s stock had its “buy” rating reaffirmed by equities researchers at JPMorgan Chase & Co. in a research report issued on Monday.
Several other research analysts also recently issued reports on ROG. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Roche Holding in a research note on Tuesday, July 19th. Citigroup Inc. reiterated a “buy” rating on shares of Roche Holding in a research note on Wednesday, July 27th.
Shares of Roche Holding (VTX:ROG) traded up 1.13% during midday trading on Monday, hitting CHK 241.00. 1,793,064 shares of the stock traded hands. The firm has a market capitalization of CHK 205.37 billion and a PE ratio of 22.27. The company’s 50-day moving average is CHK 241.43 and its 200 day moving average is CHK 246.09. Roche Holding has a 52 week low of CHK 229.90 and a 52 week high of CHK 281.40.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/roche-holding-ltd-rog-given-buy-rating-at-jpmorgan-chase-co.html
About Roche Holding
Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.